Study of LP-184 in Patients With Advanced Solid Tumors

The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available. The secondary objectives are to characterize the PK of LP-184 and its metabolites in plasma and assess clinical activity of LP-184. Participants will receive LP-184 infusion during Day 1 and Day 8 of each 21-day cycle, for a minimum of two cycles. Patients will be monitored for safety, PK, and clinical activity

Trial Details

NCT ID
NCT05933265
Phase
PHASE1 / PHASE2
Sponsor
Lantern Pharma Inc.
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • LP-184
  • Spironolactone
  • Olaparib
Locations (sample)
  • Springdale, Arkansas, United States|36.18674,-94.12881
  • Los Alamitos, California, United States|33.80307,-118.07256
  • Rolling Meadows, Illinois, United States|42.08419,-88.01313
  • Indianapolis, Indiana, United States|39.76838,-86.15804
  • Louisville, Kentucky, United States|38.25424,-85.75941

Key Eligibility Criteria

  • ≥18 years of age at the time of consent
  • Provided signed written ICF and voluntary consent prior to any mandatory study-specific procedures, sampling, and analyses.
  • Have a histologically or cytologically documented advanced solid tumor that has relapsed from or is refractory to standard treatment, or for which …
  • Note: patients with certain tumor types such as those with relatively high prevalence of DDR gene alterations and/or PTGR1 over expression (e.g., t…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →